These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 16022491)

  • 1. A method for the obtaining of increased viscosity eye drops containing amikacin.
    Sikora A; Oszczapowicz I; Tejchman B; Grzechnik M
    Acta Pol Pharm; 2005; 62(1):31-7. PubMed ID: 16022491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability of cefuroxime in 1% and 5% buffered eye drops determined with HPLC method.
    Kodym A; Wiśniewski A; Knioła D; Olejniczak M
    Acta Pol Pharm; 2011; 68(4):555-64. PubMed ID: 21796938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physical and chemical properties and stability of sodium cefazolin in buffered eye drops determined with HPLC method.
    Kodym A; Bilski P; Domańska A; Hełminiak Ł; Jabłońska M; Jachymska A
    Acta Pol Pharm; 2012; 69(1):95-105. PubMed ID: 22574512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technology of eye drops containing metronidazole.
    Kodym A; Kaczyńska-Dyba E; Kubiak B; Kukuła H
    Acta Pol Pharm; 2011; 68(1):109-14. PubMed ID: 21485708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technology of eye drops containing aloe (Aloe arborescens Mill.--Liliaceae) and eye drops containing both aloe and neomycin sulphate.
    Kodym A; Marcinkowski A; Kukuła H
    Acta Pol Pharm; 2003; 60(1):31-9. PubMed ID: 12848365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability of ceftazidime in 1% and 5% buffered eye drops determined with HPLC method.
    Kodym A; Hapka-Zmich D; Gołab M; Gwizdala M
    Acta Pol Pharm; 2011; 68(1):99-107. PubMed ID: 21485707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of additives and storage temperature on physicochemical and microbiological properties of eye drops containing cefazolin.
    Kodym A; Zawisza T; Buźka K; Kukuła H
    Acta Pol Pharm; 2006; 63(3):225-34. PubMed ID: 20085229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of cefepime in aqueous eye drops.
    Kodym A; Pawłowska M; Rumiński JK; Bartosińska A; Kieliba A
    Pharmazie; 2011 Jan; 66(1):17-23. PubMed ID: 21391430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of additives and storage temperature on physicochemical and microbiological properties of eye drops containing ceftazidime.
    Kodym A; Zawisza T; Napierała B; Kukuła H
    Acta Pol Pharm; 2006; 63(6):507-13. PubMed ID: 17438868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fortified antibiotic (vancomycin, amikacin and ceftazidime) eye drop stability assessment at -20 degrees C].
    Chédru-Legros V; Fines-Guyon M; Chérel A; Perdriel A; Albessard F; Debruyne D; Mouriaux F
    J Fr Ophtalmol; 2007 Oct; 30(8):807-13. PubMed ID: 17978677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antibiotic stability in magistral collyria].
    Tihărău A; Voiculescu E; Vancea S; Teodorescu A; Cherecheş S
    Oftalmologia; 1990; 34(2):97-104. PubMed ID: 2101048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicochemical and microbiological properties of eye drops containing cefuroxime.
    Kodym A; Zawisza T; Taberska J; Kukuła H
    Acta Pol Pharm; 2006; 63(4):293-9. PubMed ID: 17203867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro stability of fortified ophthalmic antibiotics stored at -20 degrees C for 6 months.
    Chédru-Legros V; Fines-Guyon M; Chérel A; Perdriel A; Albessard F; Debruyne D; Mouriaux F
    Cornea; 2010 Jul; 29(7):807-11. PubMed ID: 20489598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sterility of non-preservative eye drops.
    Prabhasawat P; Chotikavanich S; Leelaporn A
    J Med Assoc Thai; 2005 Nov; 88 Suppl 9():S6-10. PubMed ID: 16681044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effect of topical antibiotic on untreated eye in experimental keratitis.
    Davis SD; Sarff LD; Hyndiuk RA
    Can J Ophthalmol; 1978 Oct; 13(4):273-6. PubMed ID: 105787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Studies on hyaluronic acid as dendifier in Shuanghuanglian eye-drops].
    Ma ML; Liu L; Sun SY
    Zhongguo Zhong Yao Za Zhi; 2005 Aug; 30(16):1246-8. PubMed ID: 16245899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of topical fixed-combination fortified vancomycin-amikacin (VA solution) to conventional separate therapy in the treatment of bacterial corneal ulcer.
    Chiang CC; Lin JM; Chen WL; Chiu YT; Tsai YY
    Eye (Lond); 2009 Feb; 23(2):294-8. PubMed ID: 18188174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the force effect of aqueous and oily eye drops.
    Müller F; Wagner M; Neubert RH
    Pharmazie; 2005 Apr; 60(4):283-7. PubMed ID: 15881609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spray dried amikacin powder for inhalation in cystic fibrosis patients: a quality by design approach for product construction.
    Belotti S; Rossi A; Colombo P; Bettini R; Rekkas D; Politis S; Colombo G; Balducci AG; Buttini F
    Int J Pharm; 2014 Aug; 471(1-2):507-15. PubMed ID: 24886692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of freeze-drying condition of amikacin solid lipid nanoparticles using D-optimal experimental design.
    Varshosaz J; Ghaffari S; Khoshayand MR; Atyabi F; Dehkordi AJ; Kobarfard F
    Pharm Dev Technol; 2012; 17(2):187-94. PubMed ID: 21047276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.